Inventiva (NASDAQ:IVA) Price Target Cut to $14.00 by Analysts at HC Wainwright

Inventiva (NASDAQ:IVA) had its target price dropped by stock analysts at HC Wainwright to $14.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price target would indicate a potential upside of 261.76% from the stock’s previous close.

Several other research analysts also recently weighed in on IVA. Truist Financial upped their price target on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Cantor Fitzgerald began coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Guggenheim upped their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $14.67.

Inventiva Trading Down 4.0%

NASDAQ:IVA opened at $3.87 on Thursday. Inventiva has a 12-month low of $2.82 and a 12-month high of $7.29. The stock has a 50-day moving average price of $3.77 and a 200 day moving average price of $4.86.

Inventiva (NASDAQ:IVA) last issued its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million during the quarter. On average, equities research analysts anticipate that Inventiva will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

Several large investors have recently made changes to their positions in IVA. Seven Fleet Capital Management LP purchased a new stake in shares of Inventiva in the first quarter worth about $1,111,000. Commonwealth Equity Services LLC boosted its stake in Inventiva by 7.0% during the third quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock valued at $332,000 after buying an additional 5,857 shares during the last quarter. Engineers Gate Manager LP grew its holdings in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Inventiva by 78.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock valued at $142,000 after buying an additional 17,000 shares in the last quarter. Finally, Platt Investment Counsel LLC purchased a new position in Inventiva during the 3rd quarter valued at approximately $45,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.